Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients
Launched by MAHIDOL UNIVERSITY · Nov 13, 2017
Trial Information
Current as of June 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults (18 years and older) with sepsis and/or septic shock according to SEPSIS-3 criteria and receive meropenem within 1 hour after diagnosis
- • Informed consent signed by patient or their legally authorized representative
- Exclusion Criteria:
- • Subjects with infective endocarditis
- • Subjects with central nervous system infection
- • Subjects who requires surgical condition within 72 hours after randomization
- • Subjects on extracorporeal membrane oxygenation (ECMO) within 3 days after randomization
- • Subjects with active seizure
- • History of receiving meropenem within 1 week prior to randomization
- • Pregnancy women and lactation
- • Known allergy to meropenem
- • Not complete a 72-hour course of empirical meropenem treatment
About Mahidol University
Mahidol University, a premier institution in Thailand, is dedicated to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the university leverages its extensive expertise in medical and health sciences to facilitate rigorous scientific investigations aimed at improving patient care and public health outcomes. With a commitment to ethical practices and collaboration, Mahidol University fosters multidisciplinary approaches, engaging a diverse array of researchers and healthcare professionals to drive meaningful advancements in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ratchathewi, Bangkok, Thailand
Patients applied
Trial Officials
Tospon Lertwattanachai, B.sc.(Pharm)
Principal Investigator
Faculty of Pharmacy, Mahidol University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials